Hay países que han actuado mejor que otros frente al COVD-19
(Se estima que) Alemania ha diagnosticado al 69% de 36.000 casos, España sólo a 5% de 560.000 casos. (hilo)
2020 mar. 24
La alta tasa de letalidad (6%) estimada para Españan es una sobreestimación
porque se han diagnósticado sólo una pequeña fracción de los positivos leves. El número de casos (reales) es enorme –más de medio millón–.
Alemania lo hizo muy bien.
El número de casos (reales) total es bajo porque comenzaron pronto a hacer la prueba a personas con síntomas leves y frenaron la transmisión. El número de muertes es del 0.3% de infectados reales (parecido a España – real 0.3%)
#COVID19 Sobre cómo los Investigadores del European Research Council
@ERC_Research ayudámos en la respuesta a la epidemia para comprender, predecir y contener el brote.
2020 mar. 25
Frontier research at the service of the coronavirus epidemic response
How can frontier science help fight the current COVID-19 outbreak? To find out, we talked to a range of ERC grantees who are working in the fields of molecular biology, virology, immunology, epidemiology, and network science. As it turns out, much of their work can be applied to the current situation and could help understand, predict and contain the outbreak.
We will add more news on ERC-funded research as they become available.
List of ERC-funded research projects related to coronavirus, epidemiology and virology as well as other relevant disciplines
Trial of a possible COVID19 prophylactic treatment
Dr Oriol Mitjà, Fight AIDS and Infectious Diseases Foundation, Spain
Dr Mitjà is leading a trial of COVID19 antiviral treatment and prophylaxis.
The COVID-19 emergency warrants the urgent development of new strategies to protect high-risk people, close contacts and health-care workers. The reason is that those infected, in 14 days, will on average pass the virus to 15% – 20% of their contacts. Our current clinical trials exploit the same strategy we use in the ERC project on syphilis. We are trying to repurpose the drugs, which have already been approved, commercialised and are on the market, for the use against this coronavirus. We use in vitro and animal model data to find the best, cheapest and safest drugs, and then to test them in human clinical trials.
BBC World Se hace eco de nuestro ensayo clínico sobre la quimioprofilaxis para proteger contra SARS-CoV-2
Our clinical trial on chemeprophylaxis to protect against SARS-CoV-2 is echoed
Ikus bideoa twitterrean bertan
This strategy is called post-exposure prophylaxis and is effective in preventing illness in a variety of microbial pathogens. We use an antiviral drug that has been shown to have an effect on coronavirus. The drug is called hydroxychloroquine. It inhibits the fusion of the virus in the host cell. Our hypothesis is that post-exposure prophylaxis with hydroxychloroquine administered to close contacts of an active case will reduce the incidence of contacts that develop the infection.
We are currently conducting a multi-centre clinical trial to evaluate the efficacy of these antiviral treatments and we will evaluate the reduction in transmissibility using a polymerase chain reaction test. Last week we started with the recruitment of patients and we expect to have the first results in about 3-4 weeks.
More on the research1
If the results are positive it could be widely used in any all settings and have the potential to be a game changer in the fight against COVID-19 worldwide. The study is done in coordination with the WHO and five related trials around the world. I have always had interest in neglected tropical diseases and strategies to control the transmission of infectious diseases.
I used to conduct research on treponema pertenue which causes a disease that affects children in Africa and Oceania. I also developed a line of research on syphilis and other sexually transmitted infections. My ERC project aims to discover and repurpose drugs to treat syphilis. We are conducting studies to find new molecules that are effective against the bacteria that causes this disease as there is currently a shortage of new medicines to treat syphilis.
Oriol Mitjà was awarded ERC Starting Grant in 2019.
1 Ikus Use of antiviral drugs to reduce COVID-19 transmission: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30114-5/fulltext.